smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the close of its seed financing round of €1.2 million from Boehringer Ingelheim
A biotech advancing small molecule antibiotics through preclinical studies has closed its seed financing round of €1.2million ($1.3million) from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF).
Investment from Boehringer Ingelheim Venture Fund, Evotec SE, and Novo Holdings REPAIR Impact Fund Funding will support continued advancement of Centauri's antimicrobial resistance research